Invivogen
Menu

RANKL Reporter HEK 293 Cells

HEK-Blue™ RANKL Cells Unit size Cat. code Docs Qty Price
Human & Mouse RANKL Reporter Cells
3-7 x 10e6 cells
hkb-rankl
+-
$1,304.00

RANKL Reporter Cells

HEK-Blue RANKL Cells signaling pathway
HEK-Blue™ RANKL Cells signaling pathway

HEK-Blue™ RANKL cells were engineered from the human embryonic kidney HEK293 cell line to detect bioactive human and murine RANKL by monitoring the activation of the NF-κB and AP-1 pathways. In addition, these cells can be used for screening anti-RANKL antibodies, or inhibitors targeting the RANKL/RANK signaling pathway. 
Receptor Activator of NF-κB Ligand (RANKL) exists as a soluble or transmembrane protein produced by osteoblasts and activated T cells [1]. RANKL binding to its receptor RANK and the subsequent signaling events play a pivotal role in bone remodeling and dendritic cell survival, thereby enhancing the induction of T cell responses [1]. 

More details More details

 

Cell line description:

HEK-Blue™ RANKL cells were generated by stable transfection of human embryonic kidney HEK 293 cell line with the human gene for RANK (with all three functional TRAF-binding motifs) and an NF-κB/AP1-inducible SEAP (secreted embryonic alkaline phosphatase) reporter gene.
The binding of RANKL to its receptor on the surface of HEK-Blue™ RANKL cells triggers a signaling cascade leading to the activation of NF-κB/AP1, and the subsequent production of SEAP.  For your convenience, InvivoGen provides QUANTI‑Blue™ Solution, an easy and rapid means to detect and quantify SEAP activity in the cell culture supernatant.  

 

Features of HEK-Blue™ RANKL cells:

  • Fully functional RANKL signaling pathway
  • Readily assessable SEAP reporter activity
  • Functionally tested
  • Guaranteed mycoplasma-free

Applications of HEK-Blue™ RANKL cells:

  • Detection of both human and mouse RANKL
  • Screening of anti-RANKL antibodies
  • Screening of inhibitors targeting RANKL/RANK signaling

 

References:

1. Cheng ML. & Fong L.,  2014. Effects of RANKL-targeted therapy in immunity and cancer. Front. Oncol. 3:329.
2. Ahern E.et al., 2018. Roles of the RANKL-RANK axis in anti-tumour immunity — implications for therapy. Nat. Rev. Clin. Oncol. 15:676-93.
3. Nakai Y.et al., 2019. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7:1.

Figures

Evaluation of RANKL response in HEK-Blue™ RANKL Cells
Evaluation of RANKL response in HEK-Blue™ RANKL Cells

Dose-response of HEK-Blue™ RANKL cells to recombinant RANKL.

Cells were stimulated with increasing concentrations of recombinant human or murine RANKL. After overnight incubation, the NF-κB response was determined using QUANTI‑Blue™ Solution, a SEAP detection reagent, and reading the optical density (OD) at 630 nm. EC50 values are shown as mean ± SD.

Cytokine and TLR cellular responses
Cytokine and TLR cellular responses

Cytokine response of HEK-Blue™ RANKL cells.

Cells were stimulated with various human and murine recombinant cytokines: 10 ng/ml of hRANKL, mRANKL, hIL‑1β, mIL‑1β, 1x104 IU/ml of hIFN-α, hIFN-β, 100 ng/ml of hIFN-γ, hTNF-α, and 1 µg/ml of the TLR3 ligand Poly(I:C) HMW and the TLR5 ligand FLA-ST (flagellin from S. typhimurium). After overnight incubation, SEAP activity was assessed using QUANTI‑Blue™ Solution. 

Evaluation of RANKL/RANK signaling inhibition
Evaluation of RANKL/RANK signaling inhibition

Dose-dependent inhibition of HEK‑Blue™ RANKL cellular response using an anti-hRANKL antibody.

The antibody was incubated with HEK‑Blue™ RANKL cells  for 30 minutes prior to the addition of 10 ng/ml of hRANKL. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI‑Blue™ Solution. Data represent % inhibition of reporter activity without anti-hRANKL antibody.

Back to the top

Specifications

Antibiotic resistance: Blasticidin,  Zeocin®

Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™

Guaranteed mycoplasma-free

Specificity: human and mouse RANKL

Detection range:

  • 3 - 100 ng/ml for human RANKL
  • 1 - 100 ng/ml for murine RANKL

 

These cells are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

Dry Ice Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top

Details

Receptor Activator of NF-κB Ligand (RANKL), also known as member 11 of the tumor necrosis factor (TNF) superfamily (TNFSF11) or TNF-related activation-induced cytokine (TRANCE), exists as a transmembrane or soluble protein produced by osteoblasts and activated T cells [1]. RANKL binds to its receptor RANK via an obligate trimer configuration [1, 2].
RANKL/RANK signaling plays a pivotal role in bone remodeling and dendritic cell survival, thereby enhancing the induction of T cell responses [1]. Upon RANKL binding, RANK trimers recruit TNF receptor-associated factor (TRAF) adaptor proteins, such as TRAF6, to TRAF-binding motifs within their cytoplasmic domains [1].
The TRAF6 signaling cascade results in the activation of NF-κB and AP-1 transcription factors. Multiple efforts have focused on the development of anti‑RANKL antibodies or small‑molecule inhibitors for blocking RANKL/RANK signaling to reduce osteoporosis, prevent skeletal-related events (SREs) from bone metastasis in cancer, or improve anti-tumor immunity [1-3].

 

1. Cheng ML. & Fong L., 2014. Effects of RANKL-targeted therapy in immunity and cancer. Front. Oncol. 3:329.
2. Ahern E. et al., 2018. Roles of the RANKL-RANK axis in anti-tumour immunity — implications for therapy. Nat. Rev. Clin. Oncol. 15:676-93.
3. Nakai Y. et al., 2019. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7:1.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top
Customer Service
& Technical Support
Shopping cart is empty